近日，Journal of Critical Care 发表“A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19”一文，旨在对使用氯喹治疗新型冠状病毒肺炎的相关研究证据进行总结。
氯喹治疗新型冠状病毒肺炎的疗效及安全性的系统综述
摘要：
目的
新型冠状病毒肺炎是引起国际关注的突发公共卫生事件。尽管危重患者非常需要有效的治疗，目前尚无特效的抗病毒药物。本项系统综述旨在对使用氯喹治疗新型冠状病毒肺炎的相关研究证据进行总结。
方法
在PubMed、EMBASE和3个临床试验注册中心数据库检索应用氯喹治疗新型冠状病毒肺炎的研究。
结果
共纳入6篇研究（包括一篇短篇描述性研究、一篇体外研究、一篇社论、一篇专家共识、两篇国家指南）和23项正在中国进行的临床试验。结果表明氯喹可能能有效地在体外抑制（引起新型冠状病毒肺炎的）SARS-CoV-2病毒的复制。
结论
目前可采用治疗理论依据和临床前研究证据来评价临床研究中氯喹治疗该病的效果，并可使用临床上长期应用氯喹治疗其他疾病的证据来评价其安全性。不过，临床应用应按照《严密监测情况下紧急使用未注册疗法》里制定的准则来进行或者是按照世界卫生组织的规定在获得伦理审批后进行。当前亟需相关安全数据和高质量的临床试验数据来评估氯喹治疗新型冠状病毒肺炎的效果和安全性。
https://doi.org/10.1016/j.jcrc.2020.03.005
原文内容如下：
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Highlights
No specific pharmacological treatments are available to date for COVID-19.
Chloroquine is a widely used, safe and cheap, effective in viral infections in pre-clinical studies.
Specific pre-clinical evidence and expert opinions suggest potential use against SARS-CoV-2.
A search in trial registries shows that 23 clinical trials are ongoing in China.
There is a urgent need of high-quality clinical data from different geographic areas.
Abstract
Purpose
COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19.
Methods
PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19.
Results
We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro.
Conclusions
There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.
翻译：李秀娟
閱讀更多 中國全科醫學 的文章
